---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011589"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:39:09.734547+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lipocine Q2 net loss narrows to $2.2M; Phase 3 PPD study underway

## Summary
- Net loss of $2.2M ($0.41/diluted share) vs $3.1M loss year ago; cash $17.9M at quarter end.
- LPCN 1154 Phase 3 pivotal trial for postpartum depression dosing patients; topline Q2 2026, NDA mid-2026.
- LPCN 2401 Phase 2 proof-of-concept study in obesity planned, first patient dosing target Q3 2025.
- TLANDO NDS filed in Canada by Verity Pharma in June; Brazil license deal with Aché in April.
- Total revenue $623K (Q2) vs $90K year ago, including $500K license revenue.

## SEC filing metadata
- accession: 0001493152-25-011589
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225011589/0001493152-25-011589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225011589/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011589
- JSON: https://secwatch.observer/filing/0001493152-25-011589.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011589.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.